Hengrui Pharma signed the agreement with Merck (NYSE: MRK) — known as MSD outside of the United States and Canada — for HRS-5346, its investigational oral small molecule Lipoprotein (a), or Lp (a), ...
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...
MT Newswires on MSN2d
Merck Strikes Nearly $2 Billion Licensing Deal For Chinese Firm's Heart Disease Drug CandidateMerck (MRK) secured exclusive global rights to develop and sell China-based Jiangsu Hengrui Pharmaceuticals' heart disease drug in a deal worth up to about $2 billion. The companies said Tuesday that ...
Merck will pay the Chinese pharma company $200 million upfront and up to $1.77 billion in development, regulatory, and commercial milestone payments.
Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.
Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback